Insulin‑like growth factor‑binding proteins play a significant role in the molecular response to imatinib in chronic myeloid leukemia patients
- Yingli Ren
- Shihong Yin
- Ya Lin
- Xiucai Xu
Affiliations: Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China
- Published online on: December 20, 2019 https://doi.org/10.3892/etm.2019.8364
Copyright: © Ren
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Imatinib (IM) is successfully used in the majority of patients with chronic myeloid leukemia (CML), but some patients develop resistance to drug treatment. Insufficient apoptosis results in uncontrolled cell proliferation, which is closely associated with the occurrence of drug resistance. Therefore, it is crucial to identify new biomarkers related to drug resistance. This aim of the present study was to investigate the profile of apoptosis‑related proteins in K562 and K562/G (IM‑resistant K562 cells) cells, in order to identify new biomarkers. A human apoptosis antibody array was used to screen 46 proteins in the two cells lines, among which 20 proteins were found to be differentially expressed between K562 and K562/G cells. The major proteins included secreted caspase‑8, insulin‑like growth factor‑binding protein (IGFBP)‑1, IGFBP‑2, IGFBP‑3, caspase‑3 and p27. IGFBP‑1 IGFBP‑2 and IGFBP‑3 were selected for the follow‑up study. Subsequently, reverse transcription‑quantitative PCR analysis and western blotting were used to detect the expression levels of the IGFBPs. The results revealed that the expression levels of IGFBP‑2 and IGFBP‑3 in K562/G cells were significantly decreased compared with those in K562 cells, whereas the IGFBP‑1 level was higher. Moreover, no significant correlation was observed between IGFBP‑1 or IGFBP‑2 and the level of the BCR‑ABL fusion protein, whereas decreasing IGFBP‑3 levels were associated with increasing BCR‑ABL levels. These results suggested that IGFBP‑1, IGFBP‑2 and IGFBP‑3 could be useful novel biomarkers for IM resistance in CML.